Brokerages Set IQVIA Holdings Inc. (NYSE:IQV) Target Price at $222.00

IQVIA Holdings Inc. (NYSE:IQV) has received an average recommendation of “Moderate Buy” from the seventeen brokerages that are currently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $224.8235.

A number of research firms have recently issued reports on IQV. Evercore reiterated an “outperform” rating and set a $185.00 price target on shares of IQVIA in a research report on Wednesday, April 8th. Robert W. Baird raised their price objective on IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a research note on Wednesday, July 1st. HSBC reaffirmed a “buy” rating and set a $240.00 price objective on shares of IQVIA in a report on Monday. Morgan Stanley reissued an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price target on IQVIA in a research report on Thursday.

IQVIA Price Performance

Shares of NYSE IQV opened at $209.18 on Friday. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA has a one year low of $154.50 and a one year high of $247.04. The firm has a market capitalization of $34.91 billion, a P/E ratio of 25.92, a PEG ratio of 1.75 and a beta of 1.20. The company’s fifty day moving average is $180.59 and its two-hundred day moving average is $188.64.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. The business had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business’s revenue was up 8.4% compared to the same quarter last year. During the same quarter last year, the firm posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Analysts forecast that IQVIA will post 11.6 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has approved a share buyback plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s management believes its shares are undervalued.

Institutional Trading of IQVIA

Several institutional investors and hedge funds have recently modified their holdings of IQV. Fulton Bank N.A. raised its position in shares of IQVIA by 2.9% during the 2nd quarter. Fulton Bank N.A. now owns 6,118 shares of the medical research company’s stock worth $1,182,000 after purchasing an additional 175 shares during the last quarter. Franklin Street Advisors Inc. NC increased its position in IQVIA by 1.0% during the 2nd quarter. Franklin Street Advisors Inc. NC now owns 100,198 shares of the medical research company’s stock worth $19,360,000 after purchasing an additional 1,002 shares in the last quarter. HF Advisory Group LLC raised its stake in IQVIA by 25.7% in the 2nd quarter. HF Advisory Group LLC now owns 9,095 shares of the medical research company’s stock valued at $1,757,000 after purchasing an additional 1,861 shares during the last quarter. Oliver Luxxe Assets LLC purchased a new position in IQVIA in the 2nd quarter valued at about $3,589,000. Finally, Breakwater Capital Group lifted its holdings in IQVIA by 3.2% in the 2nd quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock valued at $401,000 after purchasing an additional 64 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.